To hear about similar clinical trials, please enter your email below
Trial Title:
A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours
NCT ID:
NCT05607563
Condition:
Advanced Tumor
Conditions: Keywords:
PM1009
TIGIT
PVRIG
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Unknown status
Study design:
Allocation:
Non-Randomized
Intervention model:
Sequential Assignment
Intervention model description:
Patients sequentially receive PM1009 120 mg, 300 mg, 600 mg, 1200 mg, intravenously, Q2W
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
PM1009 injection
Description:
Participants receive PM1009 intravenously, every 2 weeks
Arm group label:
PM1009 120 mg monotherapy
Arm group label:
PM1009 1200 mg monotherapy
Arm group label:
PM1009 300 mg monotherapy
Arm group label:
PM1009 600 mg monotherapy
Other name:
PM1009
Summary:
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and
preliminary efficacy of PM1009 for patients with advanced tumors, also to explore the
recommended Phase Ⅱ Dose（RP2D） of PM1009.
PM1009 is a new novel fully human anti-TIGIT x PVRIG bispecific antibody, containing a
wildtype IgG1 Fc and has high monovalent affinity to each target, it can binds to both
TIGIT and PVRIG overexpressing target cells and binds to TIGIT and PVRIG simultaneously.
Detailed description:
This is a single-arm, open-label, Phase I study contains dose escalation stage and dose
expansion stage.
The dose escalation stage will be following the accelerated titration design and the
classic 3+3 design, with a planned enrollment of 10 to 24 patients with advanced tumors.
The dose expansion stage will be used safe and tolerable doses, with a planned enrollment
of 30 patients with advanced tumors.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patients participate in the study voluntarily and sign informed consent；
- Male or female, aged 18 to 75 years (including boundary value);
- Subjects with advanced tumor confirmed by histology or cytology fail to receive
standard treatment, or there is no standard treatment scheme, or standard treatment
is not applicable at this stage;
- Having adequate organ function；
- ECOG score is 0-1；
- Expected survival ≥ 12 weeks；
- There is at least one assessable tumor focus.
Exclusion Criteria:
- History of severe allergic;
- Those who have received anti-TIGIT or anti-PVRIG therapy in the past;
- Patients who have grade ≥3 immune-mediated adverse event that associated with a
prior immunotherapy;
- Adverse reactions to previous antitumor therapy have not recovered to NCI-CTCAE V5.0
rating ≤ 1;
- Current definite interstitial lung disease or non-infectious pneumonitis, except for
local radiotherapy;
- Patients ever received the following treatments or drugs prior to the study
treatment:
1. Major organ surgery within 28 days prior to initiation of trial treatment;
2. Received live attenuated vaccine within 28 days prior to the study treatment;
3. Received antitumor therapy within 4 weeks prior to the study treatment;
4. Received systemic glucocorticoid within 14 days prior to the study treatment;
- Active infection was present within 14 days before starting study treatment;
- Those with known uncontrolled parenchymal or leptomeningeal metastases;
- Patients with active autoimmune disease or a history of autoimmune disease with
potential for relapse;
- Patients with other active malignancies within 5 years prior to initiation of study
treatment, except for locally treatable and cured malignancies;
- History of severe cardiovascular and cerebrovascular diseases;
- Patients with uncontrolled tumor-related pain;
- Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;
- History of allogeneic hematopoietic stem cell transplantation or allogeneic organ
transplantation;
- History of alcohol, psychotropic substance or drug abuse;
- History of psychiatric disorders or poor compliance;
- History of immunodeficiency, including a positive HIV antibody test;
- Patients with active syphilis infection;
- Patients with active hepatitis B or C;
- Pregnant or lactating women;
- Other conditions considered unsuitable for this study by investigator.
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Shanghai Orient Hospital
Address:
City:
Shanghai
Country:
China
Status:
Recruiting
Start date:
November 21, 2022
Completion date:
December 2023
Lead sponsor:
Agency:
Biotheus Inc.
Agency class:
Industry
Source:
Biotheus Inc.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05607563
